Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03749629 · ClinicalTrials.gov registry record · NA
Comparative Effectiveness of Pharmacogenomics for Treatment of Depression
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 201
- Enrollment target
NCT03749629: Completed NA study, sponsored by Massachusetts General Hospital.
NCT03749629 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 201 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03749629, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 201 participants
- Enrollment target
Study Summary
The overall goal of this study is to assess the effectiveness of a widely available and widely used combinatorial pharmacogenomic (PGx) test for the treatment of major depressive disorder. Pharmacogenomic tests use genetic information to guide medication treatment decisions. The tests inform clinicians and patients of potential gene-drug interactions by analyzing pharmacokinetic (PK) genes (how drugs are metabolized) as well as pharmacodynamic (PD) genes (how drugs work). While combinatorial PGx testing is attractive to clinicians, patients, healthcare systems, and insurers, limited data demonstrate that PGx testing will result in better outcomes compared to evidence-based guideline treatment. Therefore, the investigators will conduct a prospective randomized comparative effectiveness study of best practice guidelines plus combinatorial PGx-guided treatment versus best-practice guideline concordant treatment alone.
Interventions
- OTHER GeneSight Psychotropic test
- OTHER Canadian Network for Mood and Anxiety Treatment (CANMAT) Best Practice Guidelines
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 201 participants |
| Start Date | 2019-05-01 |
| Est. Completion | 2022-03-15 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03749629
The ClinicalTrials.gov registry entry for NCT03749629 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 201 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which GeneSight Psychotropic test is the first listed.
NCT03749629 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03749629 about?
NCT03749629 is a clinical study titled "Comparative Effectiveness of Pharmacogenomics for Treatment of Depression". The overall goal of this study is to assess the effectiveness of a widely available and widely used combinatorial pharmacogenomic (PGx) test for the treatment of major depressive disorder. Pharmacogenomic tests use genetic information to guide medication treatment decisions. The tests inform clinici...
What is the current status of trial NCT03749629?
This trial is currently completed. It is a NA study. The enrollment target is 201 participants. The study started on 2019-05-01. Estimated completion is 2022-03-15.
What interventions are being tested in trial NCT03749629?
The interventions under investigation include: GeneSight Psychotropic test (OTHER), Canadian Network for Mood and Anxiety Treatment (CANMAT) Best Practice Guidelines (OTHER).
Who is sponsoring clinical trial NCT03749629?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.